Gemeinschaftspraxis Mohm / Prange-Krex
About Gemeinschaftspraxis Mohm / Prange-Krex
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
3
Universität des Saarlandes
2
Christian Buske
1
Dr. med. Lars-Olof Muegge
1
German CLL Study Group
1
University of Jena
1
Clinical Trials at Gemeinschaftspraxis Mohm / Prange-Krex
During the past decade, Gemeinschaftspraxis Mohm / Prange-Krex conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on
average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
2011-02-15
2017-10-31
Completed
410
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
2011-07-06
2021-07-30
Completed
1,401
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
2011-12-20
2018-06-02
Completed
692
OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine
2011-11-01
2024-05-01
Active, not recruiting
1,152
Treatment Optimization in Patients With Untreated Multiple Myeloma
2013-08-01
2018-12-31
Terminated
85
Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients
2017-12-05
2024-11-01
Recruiting
388
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL
2019-01-14
2023-05-01
Active, not recruiting
46
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Gemeinschaftspraxis Mohm / Prange-Krex" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Universität des Saarlandes" with 2 trials
sponsored, "Christian Buske" with 1 trials sponsored, "Dr. med. Lars-Olof Muegge" with 1 trials sponsored and "German CLL Study Group"
with 1 trials sponsored. Other sponsors include -4 different institutions and
companies that sponsored additional 6 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Gemeinschaftspraxis Mohm / Prange-Krex"
#1 collaborator was "Amgen" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 1 trials as a collaborator, "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator and "Institute of Cancer Research, United Kingdom" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 9 trials.
Clinical Trials Conditions at Gemeinschaftspraxis Mohm / Prange-Krex
According to Clinical.Site data, the most researched conditions in "Gemeinschaftspraxis Mohm / Prange-Krex" are
"Non-Hodgkin's Lymphoma" (3 trials), "CD20+ Aggressive B-Cell Lymphoma" (1 trials), "Chronic Lymphoid Leukemia" (1 trials), "Lymphoma, Non-Hodgkin" (1 trials) and "Multiple Myeloma" (1 trials). Many other conditions were trialed in "Gemeinschaftspraxis Mohm / Prange-Krex" in a lesser frequency.
Clinical Trials Intervention Types at Gemeinschaftspraxis Mohm / Prange-Krex
Most popular intervention types in "Gemeinschaftspraxis Mohm / Prange-Krex" are "Drug" (9 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.
The name of intervention was led by "Rituximab" (3 trials), "Bendamustine" (2 trials), "Cyclophosphamide" (2 trials), "Doxorubicin" (2 trials) and "Obinutuzumab" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Gemeinschaftspraxis Mohm / Prange-Krex
The vast majority of trials in "Gemeinschaftspraxis Mohm / Prange-Krex" are
9 trials for "All" genders.
Clinical Trials Status at Gemeinschaftspraxis Mohm / Prange-Krex
Currently, there are NaN active trials in "Gemeinschaftspraxis Mohm / Prange-Krex".
undefined are not yet recruiting,
2 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 3 completed trials in Gemeinschaftspraxis Mohm / Prange-Krex,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Gemeinschaftspraxis Mohm / Prange-Krex, 0 "Phase 1"
clinical trials were conducted, 4 "Phase 2" clinical
trials and 7 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".